Health and Social Care Committee

Drugs policy: medicinal cannabis inquiry

Inquiry status: concluded

Report published on Wednesday 3 July 2019. Government Response published September 2019.

Report published

As the first part of a wider inquiry into the impact of drugs policy on public health, the Committee sought evidence on the usage of medicinal cannabis products. The Committee invited written submissions answering the following:

  • What does the current evidence base tell us about the efficacy of medicinal cannabis?
  • What plans are there for research into the medicinal use of cannabis, and what challenges are faced by that research?
  • How suitable are the current procedures for enabling the use of medicinal cannabis in appropriate cases?
  • Do practitioners have the knowledge and products available to them to confidently prescribe medicinal cannabis?
  • Is the current guidance around prescribing CDMPs fit for purpose? 
  • What can we learn from the legalisation of medicinal cannabis and its practical implementation in other countries?
  • Have recent changes in the scheduling and availability of CDMP, and media attention around this, affected public opinion and behaviours in the UK?



Latest evidence

  • 26 Mar 2019 - Drugs policy: medicinal cannabis - oral evidence | PDF version (PDF301 KB) HC 1821 | Published 01 Apr 2019

    Evidence given by Professor Andrew Goddard, President, Royal College of Physicians, Professor Finbar O'Callaghan, President, British Paediatric Neurology AssociationBaroness Blackwood, Parliamentary Under Secretary of State, Professor Chris Whitty, Chief Scientific Advisor, Department of Health and Social Care, Nick Hurd MP, Minister of State for Policing and the Fire Service, Home Office, Dr Keith Ridge, Chief Pharmaceutical Officer, NHS England

    Watch this evidence session

Next meeting(s)

There are currently no public meetings scheduled.

Receive RSS updates

Share this page